<DOC>
	<DOC>NCT01980875</DOC>
	<brief_summary>This study will evaluate the effects of idelalisib with obinutuzumab versus the combination of chlorambucil and obinutuzumab on progression-free survival (PFS) in participants with previously untreated chronic lymphocytic leukemia (CLL).</brief_summary>
	<brief_title>Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Not a candidate for fludarabine therapy based on either: 1. creatinine clearance &lt; 70 mL/min, or 2. Cumulative Illness Rating Scale score &gt; 6, by assessment of the investigator Diagnosis of Bcell CLL, with diagnosis established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) No prior therapy for CLL other than corticosteroids for disease complications. CLL that warrants treatment Presence of measurable lymphadenopathy Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 2 Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation) Known presence of myelodysplastic syndrome Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization Ongoing liver injury Ongoing druginduced pneumonitis Ongoing inflammatory bowel disease History of prior allogeneic bone marrow progenitor cell or solid organ transplantation Ongoing immunosuppressive therapy other than corticosteroids Concurrent participation in another therapeutic clinical trial Undergone major surgery within 30 days prior to randomization Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for IDELA, obinutuzumab, or chlorambucil History of noninfectious pneumonitis Received last dose of study drug on another therapeutic clinical trial within 30 days prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>